Consonance Capital Management LP Catalyst Pharmaceuticals, Inc. Transaction History

Consonance Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$3.67 - $5.7 $65.6 Million - $102 Million	-17,875,655 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.11 - $5.33 $17.9 Million - $45.2 Million	8,473,338 Added 90.12%	17,875,655 $91.2 Million
Q4 2018 Feb 14, 2019	BUY	$1.92 - $3.62 $6.45 Million - $12.2 Million	3,357,598 Added 55.55%	9,402,317 $18.1 Million
Q2 2018 Aug 14, 2018	BUY	$2.26 - $3.84 $2.37 Million - $4.03 Million	1,050,000 Added 21.02%	6,044,719 $18.9 Million
Q1 2018 May 15, 2018	BUY	$2.39 - $4.01 $1.25 Million - $2.09 Million	521,112 Added 11.65%	4,994,719 $11.9 Million
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $10.3 Million - $18.1 Million	4,104,309 Added 1111.38%	4,473,607 $17.5 Million
Q3 2017 Nov 14, 2017	BUY	$2.4 - $2.94 $886,315 - $1.09 Million	369,298	369,298 $931,000

326

94M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.22B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.